2.28
+0.21(+10.14%)
Currency In USD
Address
480 Arsenal Way
Watertown, MA 02472
United States of America
Phone
617-207-8979
Website
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
November 15, 2022
| Name | Title | Pay | Year Born |
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer | 1.07M | 1963 |
| Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer | 480,723 | 1958 |
| Ms. Mary-Alice Miller J.D. | Chief Legal Officer & Corporate Secretary | 587,108 | 1974 |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer | 774,026 | 1979 |
| Ms. Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director | 824,474 | 1981 |
| Dr. Adam D. Levy M.B.A., Ph.D. | Chief Financial Officer & Principal Financial Officer | 0 | 1966 |
| Ms. Katharine Peterson CPA | Vice President of Finance & Accounting | 0 | N/A |
| Mr. Joon Jung Ph.D. | Vice President & Head of Data Science | 0 | N/A |
| Dr. Jesper V. Olsen Ph.D. | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board | 0 | N/A |
| Mr. Bruce Close | Vice President of Quality & Compliance | 0 | N/A |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.